Incyte (INCY)
Developer of Jakafi, Opzelura, and targeted hematology, oncology, and immune-disease medicines.
$126.93
After hours+0.02 (+0.02%)
At close$126.91(+1.81%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 98.66% | 199.99M shares | |
|---|---|---|---|
| 879 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.74% | 1.50M shares | |
| 26 holders · as of Sep 17, 2026 | |||
| Other | ≈ 0.60% | 1.21M shares | |
| remainder | |||
202.70M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
879 holders · 199.99M shares · 123 new positions · 487 increased · 274 reduced · 79 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 30.76M | 15.18% | +17.9K | Aug 14, 2026 |
| BlackRock, Inc. | 18.03M | 8.90% | −945.5K | Aug 7, 2026 |
| Dodge & Cox | 11.96M | 5.90% | −295.0K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 11.02M | 5.44% | +94.2K | Aug 13, 2026 |
| State Street Corp | 9.72M | 4.80% | +81.0K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.79M | 3.84% | +31.9K | Aug 13, 2026 |
| AQR Capital Management LLC | 5.32M | 2.63% | −487.0K | Aug 14, 2026 |
| Geode Capital Management, LLC | 4.75M | 2.34% | +47.6K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Felix J. Bakerincl. Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC +4 more | 15.60% | 31.23M | 13D | May 11, 2026 |
| BlackRock, Inc. | 8.90% | 17.08M | Nov 8, 2024 | |
| Vanguard Capital Management | 6.32% | 12.59M | 13G | Apr 30, 2026 |
| Dodge & Cox | 6.20% | 12.25M | 13G | May 14, 2026 |
| State Street Corporation | 5.50% | 10.55M | Oct 17, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale · 2 lots | 23,218 | $120.49 | 183,200 |
| Aug 19, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale | 10,801 | $125.56 | 183,200 |
| Aug 12, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale | 10,803 | $120.04 | 194,001 |
| Aug 5, 2026 | Patrick A. Mayesofficer: EVP & Chief Scientific Officer | Sale | 2,207 | $123.99 | 61,441 |
| Aug 5, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale | 10,640 | $122.69 | 204,804 |
| Jul 31, 2026 | Patrick A. Mayesofficer: EVP & Chief Scientific Officer | Sale · 11 lots | 41,899 | $119.46 | 61,441 |
| Aug 3, 2026 | Patrick A. Mayesofficer: EVP & Chief Scientific Officer | Sale | 6,055 | $120.43 | 61,441 |
| Jul 31, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale | 15,888 | $119.70 | 215,444 |
| Jul 16, 2026 | Mohamed Khairie Issaofficer: EVP, Head of U.S. Commercial | Sale | 1,093 | $115.01 | 63,940 |
| Jul 16, 2026 | Steven H. Steinofficer: CMO & Head of Late-Stage Dev. | Sale | 1,877 | $114.73 | 21,118 |
House and Senate disclosures
Not reported.